StockNews.com cut shares of Charles River Laboratories International (NYSE:CRL – Free Report) from a buy rating to a hold rating in a research note released on Friday.
Other equities analysts have also recently issued reports about the company. Mizuho assumed coverage on Charles River Laboratories International in a research report on Friday, June 7th. They issued a neutral rating and a $235.00 price target for the company. Argus lifted their price objective on Charles River Laboratories International from $240.00 to $290.00 and gave the company a buy rating in a research note on Monday, March 18th. Guggenheim lowered Charles River Laboratories International from a buy rating to a neutral rating in a research note on Thursday, February 15th. Robert W. Baird dropped their price objective on Charles River Laboratories International from $282.00 to $270.00 and set an outperform rating for the company in a research note on Friday, May 10th. Finally, Citigroup lifted their price target on Charles River Laboratories International from $215.00 to $250.00 and gave the stock a neutral rating in a research note on Thursday, February 15th. Six research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of Moderate Buy and an average target price of $256.38.
Charles River Laboratories International Stock Performance
Shares of NYSE CRL traded down $2.97 during mid-day trading on Friday, hitting $209.47. The company had a trading volume of 407,102 shares, compared to its average volume of 551,956. The company has a market capitalization of $10.79 billion, a price-to-earnings ratio of 24.47, a P/E/G ratio of 2.02 and a beta of 1.40. Charles River Laboratories International has a 1 year low of $161.65 and a 1 year high of $275.00. The company has a current ratio of 1.75, a quick ratio of 1.37 and a debt-to-equity ratio of 0.73. The stock’s 50-day moving average price is $227.31 and its 200-day moving average price is $231.81.
Charles River Laboratories International (NYSE:CRL – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating the consensus estimate of $2.05 by $0.22. The company had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. On average, sell-side analysts forecast that Charles River Laboratories International will post 11 earnings per share for the current year.
Insider Transactions at Charles River Laboratories International
In other news, EVP Joseph W. Laplume sold 1,304 shares of Charles River Laboratories International stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the transaction, the executive vice president now owns 23,276 shares in the company, valued at $5,282,953.72. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 1.30% of the company’s stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of the business. Czech National Bank increased its holdings in Charles River Laboratories International by 0.5% during the 1st quarter. Czech National Bank now owns 9,025 shares of the medical research company’s stock valued at $2,445,000 after purchasing an additional 41 shares during the period. Cardinal Capital Management increased its holdings in Charles River Laboratories International by 0.6% during the 4th quarter. Cardinal Capital Management now owns 8,450 shares of the medical research company’s stock valued at $1,998,000 after purchasing an additional 47 shares during the period. Massmutual Trust Co. FSB ADV increased its holdings in Charles River Laboratories International by 21.5% during the 4th quarter. Massmutual Trust Co. FSB ADV now owns 328 shares of the medical research company’s stock valued at $78,000 after purchasing an additional 58 shares during the period. Patriot Financial Group Insurance Agency LLC increased its holdings in Charles River Laboratories International by 5.7% during the 4th quarter. Patriot Financial Group Insurance Agency LLC now owns 1,126 shares of the medical research company’s stock valued at $266,000 after purchasing an additional 61 shares during the period. Finally, Dumont & Blake Investment Advisors LLC increased its holdings in Charles River Laboratories International by 1.4% during the 1st quarter. Dumont & Blake Investment Advisors LLC now owns 4,415 shares of the medical research company’s stock valued at $1,196,000 after purchasing an additional 62 shares during the period. Hedge funds and other institutional investors own 98.91% of the company’s stock.
About Charles River Laboratories International
Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).